Borrowings - 2024-1 CLO Debt (Details) - USD ($)	9 Months Ended
	Sep. 30, 2025		Dec. 31, 2024		Nov. 21, 2024
Debt Instrument [Line Items]
Aggregate Principal Committed	$ 10,007,500,000		$ 9,307,500,000
Principal outstanding	7,669,446,000		7,093,864,000
Investments at fair value	13,809,636,000		13,092,518,000
Restricted cash	71,893,000		2,499,000
Cash and cash equivalents	249,891,000		229,606,000
Total assets	14,256,287,000		13,472,224,000
Debt	7,656,956,000		7,056,091,000
Unamortized Debt Issuance Costs (including premiums and discounts)	35,046,000		34,877,000
Interest payable	58,367,000		53,958,000
Total liabilities	7,986,711,000		7,395,703,000
2024-1 Issuer
Debt Instrument [Line Items]
Investments at fair value	744,538,000		736,551,000
Restricted cash	71,893,000		2,499,000
Cash and cash equivalents	71,893,000		2,499,000
Total assets	826,609,000		747,318,000
Debt	455,237,000		455,083,000
Unamortized Debt Issuance Costs (including premiums and discounts)	2,264,000		2,417,000
Interest payable	5,364,000		3,125,000
Total liabilities	460,601,000		458,208,000
Non-controlled/non-affiliated investments
Debt Instrument [Line Items]
Investments at fair value	13,770,027,000	[1],[2]	13,063,171,000	[3],[4]
Interest receivable from non-controlled/non-affiliated investments	105,197,000		112,046,000
Non-controlled/non-affiliated investments | 2024-1 Issuer
Debt Instrument [Line Items]
Investments at fair value	744,538,000		736,551,000
Interest receivable from non-controlled/non-affiliated investments	10,178,000		8,268,000
2024-1 CLO Debt
Debt Instrument [Line Items]
Aggregate Principal Committed	457,500,000		457,500,000
Principal outstanding	746,770,000
Debt	455,237,000		455,083,000
Unamortized Debt Issuance Costs (including premiums and discounts)	2,263,000		$ 2,417,000
Secured debt | 2024-1 CLO Debt
Debt Instrument [Line Items]
Aggregate Principal Committed					$ 746,800,000
Principal outstanding	510,000,000
Secured debt | 2024-1 CLO, Class A Notes, Senior Secured Floating Rate
Debt Instrument [Line Items]
Principal outstanding	$ 0
Basis spread on variable rate	151.00%
Secured debt | 2024-1 CLO, Class A-L Loans, Senior Secured Floating Rate
Debt Instrument [Line Items]
Principal outstanding	$ 412,500,000
Basis spread on variable rate	151.00%
Secured debt | 2024-1 CLO, Class B Notes, Senior Secured Floating Rate
Debt Instrument [Line Items]
Principal outstanding	$ 45,000,000
Basis spread on variable rate	178.00%
Secured debt | 2024-1 CLO, Class C Notes, Mezzanine Secured Deferrable Floating Rate
Debt Instrument [Line Items]
Principal outstanding	$ 52,500,000
Basis spread on variable rate	200.00%
Subordinated Debt | 2024-1 CLO Debt
Debt Instrument [Line Items]
Principal outstanding	$ 236,770,000

[1] Unless otherwise indicated, all debt and equity investments held by the Company (which such term “Company” shall include the Company’s consolidated subsidiaries for purposes of this Condensed Consolidated Schedule of Investments) are denominated in U.S. dollars. As of September 30, 2025, the Company had investments denominated in Canadian Dollars (CAD), Euros (EUR), British Pounds (GBP), Danish Krone (DKK), Swedish Krona (SEK), Norwegian Krone (NOK), and Australian Dollars (AUD). All debt investments are income producing unless otherwise indicated. All equity investments are non-income producing unless otherwise noted. Certain portfolio company investments are subject to contractual restrictions on sales. The total par amount (in thousands) is presented for debt investments, while the number of shares or units (in whole amounts) owned is presented for equity investments. Each of the Company’s investments is pledged as collateral, under one or more of its credit facilities unless otherwise indicated.

[2] All securities are exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), excluding Axsome Therapeutics, Inc. - Common Stock, and may be deemed to be “restricted securities.” As of September 30, 2025, the aggregate fair value of these securities is $13,808.0 million or 220.23% of the Company’s net assets. The initial acquisition dates have been included for such securities.

[3] All securities are exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), and may be deemed to be “restricted securities.” As of December 31, 2024, the aggregate fair value of these securities is $13,092.5 million or 215.43% of the Company’s net assets. The initial acquisition dates have been included for such securities.

[4] Unless otherwise indicated, all debt and equity investments held by the Company (which such term “Company” shall include the Company’s consolidated subsidiaries for purposes of this Condensed Consolidated Schedule of Investments) are denominated in dollars. As of December 31, 2024, the Company had investments denominated in Canadian Dollars (CAD), Euros (EUR), British Pounds (GBP), Danish Krone (DKK), Swedish Krona (SEK), Norwegian Krone (NOK), and Australian Dollars (AUD). All debt investments are income producing unless otherwise indicated. All equity investments are non-income producing unless otherwise noted. Certain portfolio company investments are subject to contractual restrictions on sales. The total par amount (in thousands) is presented for debt investments, while the number of shares or units (in whole amounts) owned is presented for equity investments. Each of the Company’s investments is pledged as collateral, under one or more of its credit facilities unless otherwise indicated.